CEL-SCI Corporation (CVM) is a clinical-stage cancer immunotherapy company based in Vienna, Virginia, whose lead candidate Multikine is being developed as a pre-surgery treatment for locally advanced head and neck cancer. The company has no product revenue and funds itself through equity sales. On Wednesday, the stock traded at $1.40, down $0.45 or 24.32% from the prior close of $1.85, extending a reversal that began late Tuesday. With a market value of roughly $25 million on 17.59 million shares, no verified news or fundamental catalyst was found to explain the decline; the move is best read as a violent unwind of a speculative two-day advance in an extremely thin micro-cap.
No fresh company press release, SEC filing, analyst rating change, financing announcement, or regulatory development appeared ahead of Wednesday's selling. The most recent corporate release was a keynote-invitation notice dated November 10, and the last substantive clinical update came in late October, when CEL-SCI presented Phase 3 biomarker data showing a 73.4% five-year survival rate in a selected patient population. None of that material is new, and none of it changed the investment case this week.
What did change was positioning. The stock climbed 29.7% on Monday and another 11.5% on Tuesday, a combined gain of about 45% from Friday's $1.28 close, without a corresponding announcement. That pattern — a sharp, news-free vertical move on 1.17 million and 1.49 million shares against a 10-day average near 107,000 — is consistent with speculative momentum trading in a low-float name rather than a fundamental re-rating. Wednesday's decline is likely profit-taking by short-horizon holders, with liquidity thin enough that one-minute prints around midday were running in the low thousands of shares, a condition that magnifies both directions of travel.
CEL-SCI's capital structure explains why fast gains in the shares have tended to fade. The company has raised money repeatedly through best-efforts offerings, including a $7.2 million sale of 6 million shares at $1.20 and a subsequent $2.5 million raise priced at $1.00. Each event reset the equity base and created a pool of holders sitting on quick gains. With cash reserves modest relative to an annual net loss above $20 million and a 212-patient confirmatory registration study still to be funded, the market treats sharp rallies as an opportunity for existing holders to exit and for the company to price new capital. That dynamic is consistent with the speed of this week's round trip, though no financing was announced Wednesday.
Volume during the advance was exceptional and clearly retail-driven. Tuesday's 1.49 million shares and Monday's 1.17 million dwarfed the roughly 100,000-share daily norm, and the stock traded as high as $2.14 intraday Tuesday before closing at $1.85. The retreat toward $1.40 retraced most of that gap but did not erase it: shares remain about 9% above Friday's close, and they sit above the 20-day moving average near $1.31, which now acts as the nearest reference point for support. Momentum indicators that had turned sharply higher early in the week have flattened. The move was idiosyncratic for a single-name biotech with no read-through to large-cap indices or broad healthcare benchmarks, whose moves are measured in fractions of a percent on a typical session.
The score runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news and an extreme, rare move. This event scores 37 out of 100. The verified news component is essentially absent: nothing new, material, or company-specific was published to justify a 24% decline, and the surrounding corporate developments were routine updates. The price move, by contrast, was notable — roughly five times the stock's average absolute daily change of about 4.9% across the last 70 sessions. A move of this magnitude has occurred only once in that span, the 29.7% gain two sessions earlier. A missing catalyst combined with a rare but not unprecedented swing produces a mid-range score.
Attention now turns to fiscal fourth-quarter and full-year results for the period ended September 30, expected in early December. Investors will focus on cash balances, operating burn, and whether enrollment in the 212-patient confirmatory registration study has actually begun after repeated delays in guidance. Two analysts currently rate the shares a Buy, and no estimate revisions have been recorded in recent weeks. Key risks include another discounted equity raise, further dilution from existing warrants, regulatory setbacks on the Saudi Breakthrough Medicine pathway pursued with partner Amarox, and the possibility that thin liquidity produces further double-digit swings unrelated to fundamentals.
Tickeron's Trending AI Robots page curates the automated strategies delivering the strongest results under present market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the top performers earn a place in this selection. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup changes as market conditions shift. Reviewing the current roster is a practical way to see how systematic approaches are positioned across equities, including volatile small caps.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CVM saw its Momentum Indicator move above the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In 85 of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CVM's RSI Oscillator exited the oversold zone, 29 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 64 of 77 cases where CVM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CVM just turned positive on November 16, 2026. Looking at past instances where CVM's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Following a +44.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVM advanced for three days, in 182 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CVM moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CVM crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CVM broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CVM entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. CVM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.328) is normal, around the industry mean (3.592). P/E Ratio (-0.858) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of immunotherapy products for the treatment of cancer and infectious diseases
Industry Biotechnology